Cargando…

Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol

Statins have been shown to be effective in reducing cardiovascular events. Their magnitude of benefits has been proportionate to the reduction in low-density lipoprotein cholesterol (LDL-c). Intensive lipid-lowering therapies using ezetimibe and more recently proprotein convertase subtilisin kexin 9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdalwahab, Ahmed, Al-atta, Ayman, Zaman, Azfar, Alkhalil, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462038/ https://www.ncbi.nlm.nih.gov/pubmed/34621492 http://dx.doi.org/10.4330/wjc.v13.i9.472

Ejemplares similares

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
por: Sharma, Rakesh K, et al.
Publicado: (2009)

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
por: Hu, Xiangming, et al.
Publicado: (2022)

Influence of menopause on high density lipoprotein-cholesterol and lipids.
por: Kim, C. J., et al.
Publicado: (2000)

Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population
por: Tian, Li, et al.
Publicado: (2010)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Lipid lowering in patients 75 years and older
por: Makhmudova, Umidakhon, et al.
Publicado: (2021)

Low-density lipoprotein cholesterol lowering treatment: the current approach
por: Crismaru, Irina, et al.
Publicado: (2020)

Rhodosporidium toruloides - A potential red yeast chassis for lipids and beyond
por: Wen, Zhiqiang, et al.
Publicado: (2020)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy
por: Takaeko, Yuji, et al.
Publicado: (2020)

Dysphagia: Thinking outside the box
por: Philpott, Hamish, et al.
Publicado: (2017)

Carbamylated lipoproteins in diabetes
por: Denimal, Damien
Publicado: (2023)

Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
por: Son, Jang Won, et al.
Publicado: (2013)

Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease
por: Shui, Xing, et al.
Publicado: (2023)

Meta‐Analysis of Intensive Lipid‐Lowering Therapy in Patients With Polyvascular Disease
por: Alkhalil, Mohammad, et al.
Publicado: (2021)

Smoking in Renal Transplantation; Facts Beyond Myth
por: Aref, Ahmed, et al.
Publicado: (2017)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome
por: Wang, Qinqin, et al.
Publicado: (2020)

Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography
por: WANG, Yao, et al.
Publicado: (2020)

Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
por: Elsadek Seaoud, Elshaimaa Aly M., et al.
Publicado: (2022)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome
por: Biswas, Hope H., et al.
Publicado: (2015)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

Remnant cholesterol associates with hypertension beyond low-density lipoprotein cholesterol among the general US adult population
por: Shi, Liu, et al.
Publicado: (2023)

Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients
por: Penumarthy, Swati, et al.
Publicado: (2013)

Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
por: Khan, Safi U., et al.
Publicado: (2019)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Molecular Mechanisms of Cellular Cholesterol Efflux
por: Phillips, Michael C.
Publicado: (2014)

Triglycerides, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol in rats exposed to premium motor spirit fumes
por: Aberare, Ogbevire L., et al.
Publicado: (2011)

Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
por: Yan, Xiaowei, et al.
Publicado: (2019)

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
por: Bays, Harold E
Publicado: (2014)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Catabolism and biotechnological applications of cholesterol degrading bacteria
por: García, J. L., et al.
Publicado: (2012)

Low Density Lipoprotein-Cholesterol/High Density Lipoprotein-Cholesterol Ratio Predicts Plaque Vulnerability in Patients With Stable Angina
por: Kim, Jeong Hun, et al.
Publicado: (2012)

Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction
por: Sigdel, Manoj, et al.
Publicado: (2012)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_be4flfd0c4qp7gf62h6ef7lqjd